In addition, Atara Biotherapeutics hired Mr. Klima as its Senior Vice President of worldwide commercial strategy and operations in 2018. Mr. Klima worked as Navidea Biopharmaceuticals Ltd.’s senior vice president and a chief commercial officer from 2015 to 2017. (acquired by Cardinal Health). Mr. Klima is a graduate of Western State College with a degree in Business Administration and Marketing.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative therapies for patients with serious diseases. The Company’s lead program, patisiran, is a potent inhibitor of the enzyme RNase. It is in Phase 3 development for treating hereditary ATTR amyloidosis, a rare and severe disease. It has completed enrollment of the first of two planned pivotal clinical studies for this indication. In addition, the Company is developing its second product candidate, brigluxtaq, to treat Non-Hodgkin Lymphoma (NHL), another severe disease. Brigluxtaq is an inhibitor of Caspase, another enzyme essential to cell death.

The post Thomas J. Klima has been named Chief Commercial and Operating Officer of bluebird bio (BLUE). BLUE is trading at $4.71 appeared first on Best Stocks.